http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-057915-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_baee372c55802742f9582e25c15ff11a |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4178 |
| filingDate | 2006-11-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_270ef3a878df070a20f7f4b493d69848 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_36ef402691a136992861d88523365c8e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2fc5e63376681f76c1d120562e5c723a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d7aea85f743d00c672001dfb94abd5a3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6ff457b488e72422822c46d9596dbdb8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bf4f2a2adc98a8e740221b46c5ca6a58 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_645f6a709f933f7cbe28720fff284913 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_978921ed5892ccf6bd2e1eeda68ff543 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1f820b6f2bfcdd57dab5914a61c8f08a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_55ea2e48bed6d4b1ec125524b3e31b16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2606fdf8b23571555850c5b91631e516 |
| publicationDate | 2007-12-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-057915-A1 |
| titleOfInvention | COMPOSED WITH CINAMIDE STRUCTURE OF TWO CYCLES WITH INHIBITORY ACTIVITY OF THE PRODUCTION OF ABETA40 AND ABETA42, A PHARMACEUTICAL AGENT THAT UNDERSTANDS IT AND THE USE OF THIS IN THE TREATMENT OF MENTAL AND NEURODEGENERATIVE DISEASES. |
| abstract | A compound with two-cycle cinnamide structure and a pharmaceutical agent comprising the compound as active component. The two-cycle cinnamide structure compound is represented by the general formula (1) where ----- represents a single bond or a double bond; Ar1 represents a phenyl group or a pyridinyl group that may be substituted with 1 to 3 substituents; R1 and R2 each represents a C1-6 alkyl, hydroxyl, or the like group; Z represents methylene or vinyl, which may be substituted with 1 or 2 substituents selected from the group of substituents A1, an O atom, or an imino group which may be substituted with a substituent selected from the group of substituents A1; and p, qyr each represents an integer from 0 to 2, which has an effect that reduces the production of Abeta40 and Abeta42 and, therefore, is especially useful as a prophylactic or therapeutic agent for a neurodegenerative disease caused by Abeta such as the disease of Alzheimer's or Down syndrome. Claim 1: A compound represented by the formula (1) or a salt acceptable for pharmacological use thereof, wherein ----- represents a single bond or a double bond; Ar1 represents a phenyl group that may be substituted with 1 to 3 substituents selected from the group of substituents A1 or a pyridinyl group that may be substituted with 1 to 3 substituents selected from the group of substituents A1; R1 and R2 are the same or different and each represents a group selected from the following group of substituents A1; Z1 represents a methylene group or vinyl group, which may be substituted with 1 or 2 substituents selected from the group of substituents A1, an O atom, or an imino group that may be substituted with a substituent selected from the group of substituents A1; and p, q and r are the same or different and represent an integer from 0 to 2; A1 substituent group: (1) a halogen atom, (2) a hydroxyl group, (3) a cyano group, (4) a C3-8 cycloalkyl group, (5) a C3-8 cycloalkoxy group, (6) a C1-6 alkyl group, where the C1-6 alkyl group may be substituted with 1 to 3 substituents selected from the group consisting of a halogen atom, hydroxyl group, cyano group, C3-8 cycloalkyl group, C1-6 alkoxy group and C3-8 cycloalkoxy group, (7) a C1-6 alkoxy group, where the C1-6 alkoxy group may be substituted with 1 to 3 substituents selected from the group consisting of a halogen atom, a hydroxyl group, cyano group, C3-8 cycloalkyl group and C3-8 cycloalkoxy group, (8) an amino group that may be substituted with one or two C1-6 alkyl groups, where C1-6 alkyl groups may be substituted with 1 to 3 halogen atoms, (9) a carbamoyl group that may be substituted with one or two C1-6 alkyl groups, where C1-6 alkyl groups may be substituted with 1 to 3 atoms of halogen, (10) a carboxyl group, (11) a C1-6 alkoxycarbonyl group, where the C1-6 alkoxy group may be substituted with 1 to 3 substituents selected from the group consisting of a halogen atom, a hydroxyl group, a cyano group, a 3-8 cycloalkyl group and a C3-8 cycloalkoxy group, (12) a C1-6 alkyl group and (13) a C1-6 alkylsulfonyl group. |
| priorityDate | 2005-11-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 40.